Taking tiny repeated doses of MDMA, hoping for subtle lifts in mood, sociability, and focus. Almost none of this has been tested directly, and the clearest evidence points to worse mental focus. Each dose raises blood pressure and heart rate and can trigger anxiety, and long-term heart-valve harm is an unsettled concern. Supply is illegal and unverified. (Full Review)

Protocol

Dose Range

~5–15 mg

Far below a recreational 75–125 mg dose; no consensus dose exists

Dosing Frequency

Weekly or less

MDMA depletes serotonin and induces tolerance; frequent dosing is cautioned against

Best Time of Day

Daytime

Stimulant action disrupts sleep; evening doses discouraged

Time to effect

Acute Effect

30–60 min

For a perceptible low dose; sub-perceptual microdoses have no defined time to benefit

Benefits

Low: Transient mood elevation and emotional openness; reduction in specific pain symptoms

Speculative: Enhanced sociability and connection; improved focus or productivity; anxiety reduction and stress resilience

Contraindications

Monoamine oxidase inhibitors (MAOIs; e.g., phenelzine, tranylcypromine, moclobemide, linezolid)

Ritonavir and other protease inhibitors

Cardiovascular disease (recent MI within 90 days, uncontrolled hypertension, heart-valve disease), arrhythmias

Serotonin-related psychiatric conditions

History of substance dependence

Significant liver impairment (Child-Pugh Class B or C)

Uncontrolled hyperthyroidism

Pregnancy or breastfeeding

Key Interactions

Serotonergic antidepressants (SSRIs: fluoxetine, sertraline, paroxetine; SNRIs: venlafaxine, duloxetine)

CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, terbinafine, ritonavir)

Other stimulants and sympathomimetics (pseudoephedrine, phenylephrine, high caffeine, amphetamine, methylphenidate)

Serotonergic supplements (5-HTP, L-tryptophan, St. John's wort, SAMe)

Risk & Side Effects

High: Anxiety and mood disturbance

Medium: Acute cardiovascular stimulation; cognitive impairment / reduced cognitive control; serotonergic depletion and tolerance

Low: Sympathomimetic side effects

Speculative: Chronic valvular heart disease; neurotoxicity with chronic exposure; dependence and compulsive use

Monitoring

Marker	Target	Why
Resting Blood Pressure	<120/80 mmHg	Tracks MDMA's pressor (BP-raising) effect and baseline cardiovascular risk
Resting Heart Rate	50–70 bpm	Detects chronic sympathetic (stress-system) overstimulation
Echocardiogram (valve assessment)	No valve thickening or regurgitation	Screens for 5-HT2B-mediated valve disease, the key theoretical long-term risk
Electrolytes incl. Sodium (Na⁺)	138–142 mmol/L	Detects hyponatremia (low sodium) risk associated with MDMA
Liver Enzymes (ALT, AST)	ALT <25 U/L (men) / <20 U/L (women)	MDMA is hepatically metabolized; flags hepatic stress
ECG (QT interval)	QTc <440 ms	Screens for arrhythmia risk from a stimulant compound

Cadence: Baseline check, reassess at ~4–8 weeks, then every 6–12 months; echocardiography repeated at least annually.

Qualitative Assessment

Mood and emotional stability between doses (watching for low-mood comedown)
Anxiety levels (a common adverse effect)
Sleep quality and onset
Cognitive clarity and focus (watching for impairment rather than improvement)
Resting heart rate trends as a sign of cumulative overstimulation
Any signs of escalating use or craving

Microdosing MDMA for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment